Cargando…
PMON171 DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Pituitary Neuroendocrine Tumoral Cells
PI3K-AKT-mTOR inhibitors have been proposed as alternative therapeutic strategy for tumors resistant to conventional drugs. The mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to display antiproliferative effects on a wide spectrum of tumors. In vitro studies demonstrated th...
Autores principales: | Mangili, Federica, Esposito, Emanuela, Treppiedi, Donatella, Catalano, Rosa, Marra, Giusy, Muro, Genesio D, Locatelli, Marco, Lania, Andrea Gerardo, Arosio, Maura, Mantovani, Giovanna, Peverelli, Erika Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625316/ http://dx.doi.org/10.1210/jendso/bvac150.1141 |
Ejemplares similares
-
DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells
por: Mangili, Federica, et al.
Publicado: (2022) -
SAT-312 Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on Akt Phosphorylation and Cell Proliferation in Pituitary Tumors
por: Mangili, Federica, et al.
Publicado: (2020) -
A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells
por: Di Muro, Genesio, et al.
Publicado: (2023) -
MON-465 SST2 Trafficking Through The Cytoskeleton: Role Of Scaffolding Proteins Filamin A And β-arrestin 2
por: Treppiedi, Donatella, et al.
Publicado: (2019) -
PMON170 Treating human primary non-functioning pituitary adenoma cells with cabergoline
por: Begalli, Federica, et al.
Publicado: (2022)